GPT-Rosalind (OpenAI) vs Olmo 3 (AI2)

Which one should you pick? Here's the full breakdown.

GPT-Rosalind (OpenAI)

C
6.8/10

OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)

Our Pick

Olmo 3 (AI2)

B
7.9/10

Allen Institute for AI's fully-open frontier reasoning models -- Olmo 3 family (2025-11-20) includes 7B and 32B sizes, four variants (Base, Think, Instruct, RLZero). Apache 2.0 with fully open data + checkpoints + training logs. Olmo 3-Think 32B matches Qwen3-32B-Thinking at 6x fewer training tokens

CategoryGPT-Rosalind (OpenAI)Olmo 3 (AI2)
Ease of Use3.06.0
Output Quality9.08.0
Value7.09.5
Features8.08.0
Overall6.87.9

Pricing Comparison

FeatureGPT-Rosalind (OpenAI)Olmo 3 (AI2)
Free TierNoYes
Starting PriceInvite only$0

Which Should You Pick?

Pick GPT-Rosalind (OpenAI) if...

  • Higher output quality (9 vs 8)

Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.

Visit GPT-Rosalind (OpenAI)

Pick Olmo 3 (AI2) if...

  • Easier to use (6 vs 3)
  • Better value for money (9.5/10)
  • Has a free tier

AI researchers doing reproducibility work, training-data studies, instruction-tuning research, or RLHF-free (RLZero) experimentation. Also valuable for academic institutions and non-profits that want to use an open-weight model whose provenance is fully auditable. Good as a teaching / learning model where inspecting checkpoints matters.

Visit Olmo 3 (AI2)

Our Verdict

Olmo 3 (AI2) is the clear winner here with 7.9/10 vs 6.8/10. GPT-Rosalind (OpenAI) isn't bad, but Olmo 3 (AI2) outperforms it across the board. Pick GPT-Rosalind (OpenAI) only if researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access.